Evidence map›Paper›PMID 35639675›Full record

SynthesisPloS one2022

Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.

Raoul Kenfack-Momo, Sebastien Kenmoe, Guy Roussel Takuissu, Jean Thierry Ebogo-Belobo, Cyprien Kengne-Ndé, Donatien Serge Mbaga, Serges Tchatchouang, Martin Gael Oyono, Josiane Kenfack-Zanguim, Robertine Lontuo Fogang and 12 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Raoul Kenfack-MomoDepartment of Biochemistry, The University of Yaounde I, Yaounde, Cameroon.
Sebastien KenmoeDepartment of Microbiology and Parasitology, University of Buea, Buea, Cameroon.ORCID 0000-0002-5536-080X
Guy Roussel TakuissuCentre for Research on Health and Priority Pathologies, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon.
Jean Thierry Ebogo-BeloboCentre for Research on Health and Priority Pathologies, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon.ORCID 0000-0002-4057-889X
Cyprien Kengne-NdéEpidemiological Surveillance, Evaluation and Research Unit, National AIDS Control Committee, Douala, Cameroon.
Donatien Serge MbagaDepartment of Microbiology, The University of Yaounde I, Yaounde, Cameroon.ORCID 0000-0002-9496-0445
Serges TchatchouangScientific Direction, Centre Pasteur of Cameroon, Yaounde, Cameroon.
Martin Gael OyonoCentre for Research on Health and Priority Pathologies, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon.ORCID 0000-0002-0990-4087
Josiane Kenfack-ZanguimDepartment of Biochemistry, The University of Yaounde I, Yaounde, Cameroon.
Robertine Lontuo FogangDepartment of Animal Biology, University of Dschang, Dschang, Cameroon.
Chris Andre Mbongue MikangueDepartment of Microbiology, The University of Yaounde I, Yaounde, Cameroon.
Elisabeth Zeuko'o MenkemDepartment of Biomedical Sciences, University of Buea, Buea, Cameroon.
Juliette Laure Ndzie OndiguiDepartment of Microbiology, The University of Yaounde I, Yaounde, Cameroon.
Ginette Irma Kame-NgasseCentre for Research on Health and Priority Pathologies, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon.
Jeannette Nina Magoudjou-PekamDepartment of Biochemistry, The University of Yaounde I, Yaounde, Cameroon.
Jean Bosco Taya-FokouDepartment of Microbiology, The University of Yaounde I, Yaounde, Cameroon.
Arnol Bowo-NgandjiDepartment of Microbiology, The University of Yaounde I, Yaounde, Cameroon.
Seraphine Nkie EsemuDepartment of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Diane Kamdem ThiomoDepartment of Biochemistry, The University of Yaounde I, Yaounde, Cameroon.
Paul Moundipa FewouDepartment of Biochemistry, The University of Yaounde I, Yaounde, Cameroon.
Lucy NdipDepartment of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Richard NjouomVirology Department, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Université de Yaoundé I · CMMinistry of Scientific Research and Innovation · CMUniversity of Buea · CMCentre Pasteur du Cameroun · CMUniversité de Dschang · CMUniversity of Douala · CM

Funding

European & Developing Countries Clinical Trials Partnership (EDCTP) TMA2019PF-2705
6 · The paper itself

Abstract

introductionDue to their common routes of transmission, human immunodeficiency virus (HIV) coinfection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) has become a major public health problem worldwide, particularly in Africa, where these viruses are endemic. Few systematic reviews report the epidemiological data of HBV and/or HCV coinfection with HIV in Africa, and none provided data on the case fatality rate (CFR) associated with this coinfection. This study was conducted to investigate the prevalence and case fatality rate of HBV and/or HCV infections among people living with human immunodeficiency virus (PLHIV) in Africa.

methodsWe conducted a systematic review of published articles in PubMed, Web of Science, African Journal Online, and African Index Medicus up to January 2022. Manual searches of references from retrieved articles and grey literature were also performed. The meta-analysis was performed using a random-effects model. Sources of heterogeneity were investigated using subgroup analysis, while funnel plots and Egger tests were performed to assess publication bias.

resultsOf the 4388 articles retrieved from the databases, 314 studies met all the inclusion criteria. The overall HBV case fatality rate estimate was 4.4% (95% CI; 0.7-10.3). The overall seroprevalences of HBV infection, HCV infection, and HBV/HCV coinfection in PLHIV were 10.5% [95% CI = 9.6-11.3], 5.4% [95% CI = 4.6-6.2], and 0.7% [95% CI = 0.3-1.0], respectively. The pooled seroprevalences of current HBsAg, current HBeAg, and acute HBV infection among PLHIV were 10.7% [95% CI = 9.8-11.6], 7.0% [95% CI = 4.7-9.7], and 3.6% [95% CI = 0.0-11.0], respectively. Based on HBV-DNA and HCV-RNA detection, the seroprevalences of HBV and HCV infection in PLHIV were 17.1% [95% CI = 11.5-23.7] and 2.5% [95% CI = 0.9-4.6], respectively. Subgroup analysis showed substantial heterogeneity.

conclusionsIn Africa, the prevalence of hepatotropic viruses, particularly HBV and HCV, is high in PLHIV, which increases the case fatality rate. African public health programs should emphasize the need to apply and comply with WHO guidelines on viral hepatitis screening and treatment in HIV-coinfected patients. REVIEW REGISTRATION: PROSPERO, CRD42021237795.

Indexed as

CoinfectionHepatitis BHepatitis CHIV InfectionsAfricaHepacivirusHepatitis B virusHIVHumans

Identifiers

PMID35639675
PMCPMC9154112
OpenAlexW4285742541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.